Higher-dose carvedilol shows promise in cats with obstructive HCM: full analysis

A new feline cardiology study is putting a familiar drug into a less familiar dosing conversation. In a prospective interventional trial published in the Journal of Feline Medicine and Surgery, researchers reported that cats with stage B1 obstructive hypertrophic cardiomyopathy whose left ventricular outflow tract obstruction persisted on standard-dose carvedilol often improved after the dose was increased to 150% to 200% of that initial regimen. Among 11 client-owned cats in the study, 10 of 11 achieved the target outflow velocity below 2.5 m/s after escalation, and investigators reported no adverse effects such as bradycardia or hypotension. (journals.sagepub.com)

The work builds on earlier research from the same group and others suggesting that beta-blockers can reduce dynamic left ventricular outflow tract obstruction in feline obstructive HCM, but that some cats remain suboptimal responders. A 2019 study found meaningful differences between carvedilol responders and non-responders, including worse baseline wall thickness, higher outflow velocities, and poorer epicardial strain in cats that did not respond adequately. More broadly, the 2020 ACVIM consensus statement underscored how common HCM is in cats, how variable its course can be, and how often treatment decisions in preclinical disease rely on limited evidence and phenotype-specific judgment. (bmcvetres.biomedcentral.com)

In the new study, investigators compared cats before treatment, after standard-dose carvedilol, and after high-dose carvedilol. Standard dosing lowered left ventricular outflow tract velocity in all cats, but median velocity still remained above the study goal, falling from 4.9 m/s before treatment to 4.3 m/s on standard dosing. After escalation, median velocity dropped to 1.6 m/s, and 10 of 11 cats reached the target threshold. Median carvedilol dosing increased from 0.29 mg/kg every 12 hours to 0.48 mg/kg every 12 hours, with the high-dose assessment performed at least 2 weeks after increasing the dose. (journals.sagepub.com)

The paper also points to biologic effects beyond Doppler measurements. Longitudinal strain improved after treatment, and cardiac troponin I concentrations fell from a median 0.334 ng/ml before treatment to 0.192 ng/ml on standard dosing and 0.018 ng/ml on high-dose carvedilol. Seven of 11 cats were within the reference interval after high-dose treatment. Of the 11 cats enrolled, five were asymptomatic before treatment and six had clinical signs, which is a reminder that even stage B1 obstructive disease can present with a mixed clinical picture in referral populations. (journals.sagepub.com)

There doesn't appear to be much published outside commentary yet on this specific paper, but the findings fit a growing thread in feline cardiology literature: obstruction burden may be modifiable, and myocardial function may improve when that burden is reduced. The authors themselves frame the work cautiously, and that caution is warranted. This was a small, single-arm study without a control group, and it focused on echo parameters and biomarkers rather than hard clinical endpoints such as congestive heart failure, arterial thromboembolism, or survival. (journals.sagepub.com)

Why it matters: For veterinary professionals, the practical takeaway is not that every cat with obstructive HCM should move immediately to higher-dose carvedilol. It's that persistent obstruction after an initial carvedilol trial may not mean the drug has failed. In carefully selected cats, especially those being followed with echocardiography and blood pressure monitoring, dose escalation may be a reasonable next step before abandoning carvedilol altogether. That could matter in a disease where left ventricular outflow tract obstruction contributes to pressure overload, mitral regurgitation, myocardial stress, and potentially ongoing injury. (bmcvetres.biomedcentral.com)

The study also raises a workflow point for general practice and referral teams alike: response assessment matters. If a cat is labeled stable because heart rate has fallen, but obstruction remains substantial on echo, clinicians may be missing an opportunity to optimize therapy. At the same time, the evidence base remains early, so discussions with pet parents should stay grounded in uncertainty, monitoring needs, and the fact that improved surrogate markers don't always translate into better long-term outcomes. (bmcvetres.biomedcentral.com)

What to watch: The next meaningful step will be larger, ideally multicenter studies that test whether higher-dose carvedilol changes clinical outcomes, helps define which cats are most likely to benefit, and clarifies where escalation fits relative to other options for carvedilol-refractory obstructive HCM. (journals.sagepub.com)